Reviva Pharmaceuticals Holdings (RVPH) Technical Analysis
$0.80▲9.59%
Market is closed - opens 7 PM, 02 Apr 2026
Insights
- Reviva Pharmaceuticals is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
- Based on analysis of the Oscillators technical indicator, the current market trend for Reviva Pharmaceuticals stock suggests that it is a good time to buy
- Based on analysis of the Moving Averages technical indicator, Reviva Pharmaceuticals stock is in a downtrend↘️
- Based on analysis of the Pivot Points, the current market trend for Reviva Pharmaceuticals stock suggests that it is a good time to buy
Analysis Summary
Oscillators
Sell
Neutral
Buy
Moving Averages
Sell
Neutral
Buy
Pivots
Sell
Neutral
Buy
Oscillators
Name | Value | Action |
|---|---|---|
Relative Strength Index | 21.04 | Buy |
Stochastic | 6.29, 4.09 | Buy |
Ultimate Oscillator | 32.32 | Neutral |
Stochastic Relative Strength Index | 12.19, 10.35 | Buy |
Moving Average Convergence Divergence | -1.07, -1.07 | Neutral |
Moving Averages
Simple Moving Average
Period (Days) | Value | Action |
|---|---|---|
10 | 0.9 | Sell |
20 | 2.0 | Sell |
50 | 4.05 | Sell |
Exponential Moving Average
Period (Days) | Value | Action |
|---|---|---|
10 | 1.1 | Sell |
20 | 1.89 | Sell |
50 | 3.83 | Sell |
Volume Weighted Moving Average
Period (Days) | Value | Action |
|---|---|---|
10 | 0.88 | Sell |
20 | 1.19 | Sell |
50 | 1.93 | Sell |
Double Exponential Moving Average
Period (Days) | Value | Action |
|---|---|---|
10 | 0.41 | Sell |
20 | 0.44 | Sell |
50 | 1.12 | Sell |
Triple Exponential Moving Average
Period (Days) | Value | Action |
|---|---|---|
10 | 0.52 | Buy |
20 | 0.27 | Sell |
50 | 0.44 | Sell |
Pivot
Pivot | Value |
|---|---|
Resistance L3 | 0.97 |
Resistance L2 | 0.88 |
Resistance L1 | 0.77 |
Pivot Point | 0.68 |
Support L1 | 0.57 |
Support L2 | 0.48 |
Support L3 | 0.37 |
*Disclaimer: The content present here is for informational purposes only, you should not construe any such information or other material as investment advisory.